Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fifty 410 vs Spry

Fifty 410
Graded #94

Higher grade

vs+14.5
Spry
Graded #408

Lower grade

The verdict

Fifty 410 takes it — 71.3/100 to 56.8/100.

Fifty 410 grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fifty 410 is a direct-to-consumer weight-loss telehealth service offering personalized compounded semaglutide and tirzepatide prescribed by licensed providers and prepared by FDA-registered 503A and 503B…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFifty 410 +32
86
54
Dose & formulationFifty 410 +8
72
64
Clinical oversightFifty 410 +25
80
55
Labs & monitoringFifty 410 +1
53
52
FulfillmentFifty 410 +10
71
61
Contract termsSpry +18
37
55
Fifty 410 · left barSpry · right bar

The numbers

MetricFifty 410Spry
WeighScore71.3/10056.8/100
GradeCC
Scorecard rank#94#408
Semaglutide$99/mo (all doses, compounded)$199/mo (starting dose, compounded)
Tirzepatide$133/mo (starting dose, compounded)$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Fifty 410

Graded #94 · C

Strengths

  • Transparent public pricing from 99 dollars per month for semaglutide
  • No membership or subscription; pay only for what you need
  • Compounded by FDA-registered 503A and 503B pharmacies
  • Fast 24 to 48 hour provider review
  • Free one to two day shipping

Where it loses points

  • Does not bill insurance directly
  • Compounded GLP-1 is not an FDA-approved finished drug
  • Specific clinician credentials are not publicly disclosed
  • Served-states list is not published on the site
  • No branded GLP-1 options
Spry

Graded #408 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard